KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Current Deferred Revenue (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Current Deferred Revenue data on record, last reported at $77.0 million in Q3 2025.

  • For Q3 2025, Current Deferred Revenue rose 1.27% year-over-year to $77.0 million; the TTM value through Sep 2025 reached $77.0 million, up 1.27%, while the annual FY2024 figure was $79.0 million, 47.73% down from the prior year.
  • Current Deferred Revenue reached $77.0 million in Q3 2025 per IONS's latest filing, up from $75.9 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $204.8 million in Q3 2023 and bottomed at $75.9 million in Q2 2025.
  • Average Current Deferred Revenue over 5 years is $102.0 million, with a median of $94.1 million recorded in 2024.
  • Peak YoY movement for Current Deferred Revenue: surged 105.83% in 2023, then tumbled 62.89% in 2024.
  • A 5-year view of Current Deferred Revenue shows it stood at $97.7 million in 2021, then decreased by 7.3% to $90.6 million in 2022, then soared by 66.85% to $151.1 million in 2023, then crashed by 47.73% to $79.0 million in 2024, then fell by 2.54% to $77.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $77.0 million in Q3 2025, $75.9 million in Q2 2025, and $81.1 million in Q1 2025.